Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received November 9, 2014
- Accepted in final form January 13, 2015
- First Published March 12, 2015.
Author Disclosures
- Yael Hacohen, MRCPCH,
- Michael Absoud, MRCPCH, PhD,
- Kumaran Deiva, MD, PhD,
- Cheryl Hemingway, MRCP, PhD,
- Petra Nytrova, MD,
- Mark Woodhall, PhD,
- Jacqueline Palace, MRCP, MD,
- Evangeline Wassmer, FRCPCH,
- Marc Tardieu, MD, PhD,
- Angela Vincent, FRS, FMedSci*,
- Ming Lim, MRCP, PhD* and
- Patrick Waters, PhD*
- On behalf of United Kingdom Childhood Inflammatory Demyelination (UK-CID) and French Kidbiosep Study Groups
- Yael Hacohen, MRCPCH,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
This work was supported by the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre based at Oxford University Hospitals NHS Trust and the University of Oxford
NONE
NONE
NONE
NONE
NONE
NONE
- Michael Absoud, MRCPCH, PhD,
M Absoud serves on the data safety monitoring board for a study sponsored by Neurim Pharmaceuticals
NONE
NONE
M Absoud sits on the editorial advisory board of the International Journal of Language & Communication Disorders
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
M Absoud received funding from the MS Society and Action Medical Research Charities
NONE
NONE
NONE
NONE
NONE
NONE
- Kumaran Deiva, MD, PhD,
NONE
NONE
Biogen Idec, travel subsidies Merck Serono, travel subsidies
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Cheryl Hemingway, MRCP, PhD,
NONE
NONE
Biogen Idec honorarium speaker contract Terumo products honorarium speaker contract Merck Serono Bayer
Journal of Paediatric Neurology editorial board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Multiple Sclerosis society Action Research
NONE
NONE
NONE
NONE
NONE
NONE
- Petra Nytrova, MD,
NONE
NONE
PN received speaker honoraria from Biogen Idec and Novartis.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
PN, her research work is supported by the Czech Ministries of Education and Health (PRVOUK-P26/LF1/4).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mark Woodhall, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Jacqueline Palace, MRCP, MD,
UK advisory board participant: 1) Merck Serono 2) Bayer Schering Pharma 3) Biogen Idec 4) Teva Pharmaceutical Industries Ltd. 5) Novartis Pharmaceuticals UK Ltd. 6) Sanofi-Aventis
NONE
Support for attending ECTRIMS Merck Serono Novartis and Biogen idec
NONE
(1) ISIS innovation Limited, a wholly-owned subsidiary of the University of Oxford, has filed a patent application (WO2013/117930 A2) to protect for the use of metabolomics as a method to diagnose and stage disease in multiple sclerosis.
NONE
NONE
In addition to advisory committees, consultant for: Ono Pharmaceuticals Ltd. Chugai Pharma Ltd. CI Consulting Biogen Idec GlaxoSmithKline
NONE
NONE
NONE
Donations to support local service development and research, none relevant to the current work: Bayer Schering Merke Serono Novartis
Department of Health Risk Sharing Scheme, Clinical Coordinator since 2002 Department of Health funding for a neuromyelitis optica service and a congenital myasthenia service
NONE
MS Society UK Guthy Jackson Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Evangeline Wassmer, FRCPCH,
NONE
NONE
commercial (Biogen, Teva, Genzyme), speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
Attended meetings (CME) supported by many pharmaceutical companies. Received travel/accommodation/speaker honoraria to attend meetings from Shire, Biogen, Teva, Genzyme, UCB and Merck Serono.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marc Tardieu, MD, PhD,
1. Scientific advisory board for Biogen, Genzyme and Novartis for new treatment in pediatric MS.
NONE
1. Travelling money for the meeting of the two scientific advisory board (two trips one in Boston one in London from Paris). One trip to Boston for Novartis advisory meeting.
European J Paediatr Neurol (editorial board) Multiple sclerosis Journal
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Angela Vincent, FRS, FMedSci*,
NONE
NONE
Occasional small honoraria, travel and speaker honoraria from Baxter International Inc and Biogen Inc
Advisory Editorial Board Neurology; Associate Editor for Brain ended 2013
Hold patent with Oxford University for LGI1/CASPR2 antibodies, licensed to Euroimmun AG, and for GABAAR antibodies, in negotiation with Euroimmun AG.
Royalties from Athena Diagnostics (MuSK assays). Royalties received from Euroimmun AG (LGI1 and CASPR2 assays) Clinical Neuroimmunology (Blackwell Publishing, 2005) and Inflammatory and Autoimmune Disorders of the Nervous System in Children (Mac Keith Press 2010). System in Children (Mac Keith Press, 2010)
NONE
Consultancy with Athena Diagnostics for assessing their antibody assays ?5K pa. Ended 2014.
Scientific conference expenses only
NONE
NONE
NONE
NONE
NIHR general support for antibody work
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ming Lim, MRCP, PhD* and
NONE
NONE
1)Travel grants from Merc Serono for attending meetings (non-profit)
NONE
NONE
NONE
NONE
Consultancy for advisory board meeting CSL Behring (non-profit entity)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Patrick Waters, PhD*
NONE
NONE
Speaker honoraria from Biogen Idec Japan and Euroimmun AG.
Frontiers in molecular innate immunity, Review editor, 1 Yr
Assays for the detection of antibodies to lgi1, Caspr2 and tag-1.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
A patent has been submitted on GABAAR.
NONE
NONE
NONE
- From the Nuffield Department of Clinical Neurosciences (Y.H., M.W., J.P., A.V., M.L., P.W.), John Radcliffe Hospital, University of Oxford, UK; Children's Neurosciences (M.A., M.L.), Evelina Children's Hospital at Guy's and St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre, London, UK; Assistance Publique Hôpitaux de Paris (K.D., M.T.), Hopitaux Universitaires Paris Sud, France; Pediatric Neurology Department and National Referral Center for Neuroinflammatory Diseases (K.D., M.T.), Université Paris Sud, Le Kremlin-Bicêtre, Paris, France; Department of Paediatric Neurology (C.H.), Great Ormond Street Hospital for Children, London, UK; Department of Neurology and Center of Clinical Neuroscience (P.N.), General University Hospital in Prague, Czech Republic; First Faculty of Medicine (P.N.), Charles University in Prague, Czech Republic; and Department of Paediatric Neurology (E.W.), Birmingham Children's Hospital, UK.
- Correspondence to Dr. Lim: ming.lim{at}gstt.nhs.uk
Article usage
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Topics Discussed
Alert Me
Recommended articles
-
Article
Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndromeEva-Maria Hennes, Matthias Baumann, Kathrin Schanda et al.Neurology, August 02, 2017 -
Article
Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeletonRussell C. Dale, Esther M. Tantsis, Vera Merheb et al.Neurology - Neuroimmunology Neuroinflammation, May 22, 2014 -
Article
Pediatric acquired CNS demyelinating syndromesFeatures associated with multiple sclerosisRogier Q. Hintzen, Russell C. Dale, Rinze F. Neuteboom et al.Neurology, August 29, 2016 -
Article
Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disordersDouglas Kazutoshi Sato, Dagoberto Callegaro, Marco Aurelio Lana-Peixoto et al.Neurology, January 10, 2014